BeiGene’s Post

Did you know why today 9/22 as a world CML day? Around 95% of chronic myelogenous leukemia (CML) patients show DNA "swapped" also called translocation between “chromosomes 9 and 22”. Part of chromosome 9 goes to 22 and part of 22 goes to 9. However, Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician. CML shouldn’t be considered as “good cancer”, let’s remember this meaningful day 9/22 and dedicate to bridge the communication disparity between physicians and CML patients. https://lnkd.in/gA-HFEUg #SUNsurvey #922CMLDAY #WCMLD23 #CureCML #breakthesilence

Missed our December webcast about Chronic Lymphocytic Leukemia (CLL)? The recording is now available online, offering valuable insights into CLL. Join Dr. Versha Banerji as she explores the latest in CLL diagnosis, treatment, and future developments. 👉 Watch the recording here: https://bit.ly/48FjIIs #cll #chroniclymphocyticleukemia #bloodcancer #webcast #webinar

In this interview, Neil E. Kay, MD, offers insights into the pathobiology, treatment, and management of double refractory chronic lymphocytic leukemia (CLL). "For most patients who are double refractory, treatment with clinically approved agents [is] short-lived. So clinical trials are probably the best way to treat your double refractory CLL patient if you have one," said Dr Kay. Access the full interview here: https://lnkd.in/eB_Qqxka #JournalofClinicalPathways #JCP #Chroniclymphocyticleukemia #CLL #CLLclincialtrials

Want to learn more about managing patients with chronic lymphocytic leukemia (CLL)? Watch this new sponsored video on updates in CLL: https://lnkd.in/dPK39eyV #LeukemiaAwareness #CLL

Today at #ASCO24, we are excited to be presenting new data on the relapsed / refractory chronic lymphocytic leukemia (#CLL) landscape. Alongside data from head-to-head clinical trials, this research will help to arm physicians with strong, clinically relevant data to help support decision-making for their patients. Learn more about our commitment to #bloodcancers like #CLL. https://bit.ly/3yrtEZ5

In a recent WebMD interview, Winship hematologist Andres Chang, MD, PhD, discusses what happens when Chronic lymphocytic leukemia (CLL) comes back. At first, symptoms of a relapse are rare, so watchful waiting is often the approach. Then, there are several paths available, including targeted therapies. Learn more: https://lnkd.in/eDtuNWy4

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia https://lnkd.in/eAZrMcgy

Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult The treatment of acute lymphoblastic leukemia (ALL) continues to evolve with the introduction of new agents to replace chemotherapy and improve outcomes. In this educational program, experts share their best practices for treating patients with ALL and then use a case-based format to review the latest data regarding management and discuss key clinical challenges. Register here: https://ow.ly/noAk50PwU2I #PER #PEROnline #PEROnlineActivities

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results https://lnkd.in/ehvYRxPv

T-cell Acute Lymphoblastic Leukemia Treatment Market Comprehensive Report 2024: Key Strategies for Growth and Future Prospects https://lnkd.in/eTBaWF8D #marketanalysis #marketresearch #marketresearchreports #businessintelligence